Lupin Limited has informed the Exchange regarding a press release dated April 08, 2026, titled "Lupin Announces Approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States ".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty Midcap 150 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lupin Limited has received final approval from the U.S. FDA for its generic Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in four dosage strengths (5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg). The company also received tentative approval for the 2.5 mg/1,000 mg dosage. The product is bioequivalent to AstraZeneca's brand drug Xigduo® XR, which is used to treat type 2 diabetes. This approval allows Lupin to market this diabetes medication in the United States, expanding their US generic portfolio.
Positive for shareholders as FDA approval enables Lupin to launch this diabetes drug in the US market, potentially driving revenue from a chronic disease medication. However, the financial impact depends on market competition and pricing in the generic space.